Delisting risk
Kiora Pharmaceuticals
Develops intravitreal photoswitch and DHODH-inhibitor candidates for retinal degeneration and inflammation.
$2.54
After-hours close−0.04 (−1.55%)
At close$2.58(−3.01%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions —Insiders 2.63%
Shares outstanding 4.43M · Float 4.17M · 94.2% free float
Institutions13F
No 13F holders on record.
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Perceptive Advisors LLC | 9.99% | 442.4K | 13G | Aug 10, 2026 ↗ |
| Alyeska Investment Group, L.P. | 9.99% | 394.7K | 13G | May 15, 2026 ↗ |
| Nantahala Capital Management, LLC | 9.99% | 438.5K | 13G | May 15, 2026 ↗ |
| ADAR1 Capital Management GP, LLCincl. Daniel Schneeberger, ADAR1 Capital Management, LLC | 9.99% | 315.1K | 13G | Nov 14, 2024 ↗ |
| Rosalind Advisors, Inc. | 9.90% | 464.7K | 13G | Feb 11, 2026 ↗ |
| ADAR1 Capital Management, LLC | 9.90% | 362.5K | 13G | Aug 14, 2025 ↗ |
| Alyeska Fund GP, LLCincl. Anand Parekh, Alyeska Investment Group, L.P. | 8.40% | 256.4K | Nov 14, 2024 ↗ | |
| Goldman Sachs & Co. LLCincl. The Goldman Sachs Group, Inc. | 6.10% | 180.8K | Nov 12, 2024 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Brian M. Strem | director, officer: President and CEO | 58.8K | 1.33% | Jul 2, 2026 |
| Eric Joseph Daniels | officer: Chief Development Officer | 31.7K | 0.72% | Apr 2, 2026 |
| Melissa Tosca | officer: CFO | 26.1K | 0.59% | Jul 2, 2026 |
4 ten-percent owners hold 2.7K shares by Form 4, outside the officers-and-directors figure above · 17 people have not refiled in the last 18 months (16.5K shares), so they are not in the figure above
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.